Naval Daver, MD

Naval G. Daver, MD is a Professor and Director of the Leukemia Research Alliance Program within the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas. As a clinical investigator, he specializes in molecular and immune-based therapies for acute myeloid leukemia and other myeloid diseases. He serves as the principal investigator for more than 25 institutional, national, and international clinical trials, including multiple studies designed to support regulatory approval and label expansion.

His research focuses on advancing personalized treatment strategies by targeting specific genetic mutations and immune pathways associated with acute myeloid leukemia. He explores novel therapeutic combinations involving targeted agents, immunotherapy, and cytotoxic treatments while investigating mechanisms of resistance. His work includes the development of monoclonal and bispecific antibodies, immune checkpoint inhibitors, CD47-targeted therapies, and approaches utilizing natural killer and T cells, as well as apoptotic-targeting treatments. He leads several of these trials at MD Anderson Cancer Center.

Dr. Daver has authored more than 400 peer-reviewed publications and serves on the editorial boards of multiple hematology journals. He is also an active leader in the field, chairing national and international conferences and educational initiatives.

Dr. Daver joined the Blood Cancers Today editorial board in 2025 as an Associate Editor to offer his expertise on topics related to myeloid malignancies.